Asset Details
Do you wish to reserve the book?
Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets
Do you wish to request the book?
Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets
2017
Overview
Abstract
Osteosarcoma is the most common primary bone malignancy in children and adolescents. Although improvements in therapeutic strategies were achieved, the outcome remains poor for most patients with metastatic or recurrent osteosarcoma. Therefore, it is imperative to identify novel and effective prognostic biomarker and therapeutic targets for the disease. Long noncoding RNAs (lncRNAs) are a novel class of RNA molecules defined as transcripts >200 nucleotides that lack protein coding potential. Many lncRNAs are deregulated in cancer and are important regulators for malignancies. Nine lncRNAs (91H, BCAR4, FGFR3-AS1, HIF2PUT, HOTTIP, HULC, MALAT-1, TUG1, UCA1) are upregulated and considered oncogenic for osteosarcoma. Loc285194 and MEG3 are two lncRNAs downregulated and as tumor suppressor for the disease. Moreover, the expressions of LINC00161 and ODRUL are associated with chemo-resistance of osteosarcoma. The mechanisms for these lncRNAs in regulating development of osteosarcoma are diverse, e.g. ceRNA, Wnt/β-catenin pathway, etc. The lncRNAs identified may serve as potential biomarkers or therapeutic targets for osteosarcoma.
Publisher
S. Karger AG,Cell Physiol Biochem Press GmbH & Co KG
Subject
Antineoplastic Agents - therapeutic use
/ Biomarkers, Tumor - genetics
/ Biomarkers, Tumor - metabolism
/ Child
/ Gene Expression Regulation, Neoplastic
/ Humans
/ Neoplasm Recurrence, Local - diagnosis
/ Neoplasm Recurrence, Local - genetics
/ Neoplasm Recurrence, Local - pathology
/ Neoplasm Recurrence, Local - therapy
/ Review
/ RNA, Long Noncoding - genetics
/ RNA, Long Noncoding - metabolism
/ Sarcoma
